Your eye is not a rigid container. It is a dynamic system, continuously producing and draining fluid to maintain the pressure — intraocular pressure, or IOP — that keeps the eye inflated, shaped, and optically functional. Normal IOP sits between 10 and 21 mmHg, measured by the gold standard of Goldmann applanation tonometry. Within this range, the eye maintains its architecture. Outside it — specifically above it — the optic nerve begins to suffer.

The fluid responsible for this balance is aqueous humor — not tears, not vitreous gel, but a clear fluid produced continuously by the ciliary body (a ring of tissue behind the iris). This fluid flows through the pupil into the anterior chamber, then drains through the trabecular meshwork, passes through Schlemm's canal, and eventually exits into the episcleral veins. The entire cycle completes roughly every 90 minutes. Approximately 2–3 microlitres are produced per minute. The balance between production and drainage is what determines IOP.

The optic nerve — which transmits visual information from approximately 1.2 million retinal ganglion cell axons to the brain — exits the eye at a structurally weak point called the lamina cribrosa. This lattice of connective tissue is permeable to nerve fibres but not to the eye's internal pressure. When IOP rises, it compresses the lamina cribrosa, distorts its pores, disrupts axoplasmic transport within the nerve fibres, and gradually starves them of nutrients. The cells die. The axons disappear. The nerve thins.

The critical clinical problem: none of this produces pain. The optic nerve has no pain receptors. The peripheral retina — where glaucomatous damage begins — has dense enough representation that the brain compensates for early cell loss through neural plasticity. Patients report no symptoms until the damage is extensive.

Glaucoma will affect an estimated 111.8 million people globally by 2040, according to the landmark systematic review by Tham et al. in Ophthalmology (2014). India contributes disproportionately — carrying a disease burden shaped by specific epidemiological and structural factors.

Primary angle-closure glaucoma (PACG) is substantially more prevalent in South Asian populations than in European or African populations. This is not incidental. South Asian eyes tend to have shorter axial lengths, shallower anterior chambers, and more anteriorly positioned lenses — anatomical features that predispose to angle crowding. In some South Asian cohort studies, PACG prevalence in adults over 40 runs at 2–4%, compared to under 0.5% in European adults of the same age.

The second factor is detection. Primary open-angle glaucoma — the most common form globally, accounting for roughly 70% of Indian glaucoma cases — produces no pain, no redness, and no perceptible visual change until late stages. In a healthcare system where routine eye examinations are not universal, and where the presenting complaint drives the consultation, glaucoma goes unexamined until patients lose significant central vision. By that point, the optic nerve damage is irreversible.

"Glaucoma" is not a single disease. It is a family of optic neuropathies sharing the same endpoint — progressive, irreversible optic nerve damage — but differing substantially in mechanism, presentation, urgency, and treatment. Understanding which type a patient has determines how urgently they need intervention.

Glaucoma diagnosis requires multiple data points. No single test is sufficient — a patient with normal IOP can have glaucoma (normal-tension), and a patient with elevated IOP may have ocular hypertension without disc damage. The clinical assessment integrates four streams of information:

Goldmann applanation tonometry (GAT) is the gold standard — a calibrated force is applied to the central cornea and the pressure required to flatten a defined area provides IOP in mmHg. Normal range: 10–21 mmHg. Values above 21 mmHg represent ocular hypertension. Values above 30 mmHg significantly increase the risk of optic nerve damage. Importantly, IOP fluctuates diurnally — peak pressures are often in the early morning. Single readings may miss peak IOP.

Central corneal thickness (CCT) affects applanation readings. Thin corneas (<520 μm) underestimate true IOP; thick corneas overestimate. Goldmann readings on thin corneas should be adjusted upward — patients with thin corneas face higher glaucoma risk than their measured IOP suggests.

The optic disc is examined through a dilated pupil using a slit lamp and a fundus lens, or via fundus photography. The critical measurement is the cup-to-disc (C/D) ratio — the proportion of the disc occupied by the central depression (cup). A normal C/D ratio is typically <0.5. A ratio >0.7, asymmetry between the two eyes of >0.2, or notching of the neuroretinal rim are signs of glaucomatous damage. The inferior and superior poles of the disc ("ISNT rule" — Inferior > Superior > Nasal > Temporal) are preferentially affected first.

OCT provides a non-contact, objective measurement of RNFL thickness around the optic disc — displayed as a thickness map with normative database comparison (colour-coded: green = normal, yellow = borderline, red = outside normal limits). OCT detects structural damage earlier than visual field testing, often by 5–7 years. It is now standard of care at any centre with access to the technology and is indispensable for monitoring subtle progression.

Automated static perimetry (Humphrey Visual Field analyser is the most widely used) maps functional sensitivity across the visual field. Glaucomatous field defects have characteristic patterns: arcuate (nerve fibre bundle) defects, nasal step defects, and paracentral scotomas. Testing is patient-dependent (attention, fatigue, and fixation affect reliability) and detects damage later than OCT — but provides functional data critical for treatment decisions and legal/driving assessments.

Glaucoma removes peripheral vision first, then advances inward. The pattern follows the anatomy of the nerve fibre bundles that arc from peripheral retina to the optic disc — the superior and inferior arcuate fibres are most vulnerable to IOP-related compression at the disc. The result is a field defect that arcs above or below the horizontal midline, classically described as an "arcuate scotoma."

What makes this particularly insidious: the brain fills in missing peripheral vision using input from the other eye and through neural interpolation. Patients genuinely do not notice the loss until the two fields no longer overlap adequately, or until central vision is threatened — which in untreated glaucoma can take 10–15 years.

The central vision preserved in end-stage glaucoma is not a good outcome. It represents a small island of functional vision surrounded by blindness — patients with end-stage glaucoma often have legal blindness despite 20/20 central acuity. Driving, mobility, and quality of life depend on peripheral vision as much as central sharpness.

All glaucoma treatment is aimed at lowering intraocular pressure — whether the patient has elevated IOP or normal-tension glaucoma, whether the mechanism is trabecular outflow resistance or increased aqueous production. The specific IOP target depends on the degree of existing damage, the rate of progression, and life expectancy: a patient with moderate glaucoma at age 75 requires a different target than a 45-year-old with the same disc damage.

The first-line treatment for most open-angle glaucoma cases. Five drug classes are in routine use, each reducing IOP through a different mechanism:

• Prostaglandin analogs (latanoprost, bimatoprost, travoprost) — most effective first-line agents; reduce IOP 25–35% by increasing uveoscleral outflow; once-daily dosing; well-tolerated systemically; may cause iris colour change and periocular skin darkening with long-term use.
• Beta-blockers (timolol, betaxolol) — reduce aqueous production; effective but contraindicated in asthma, COPD, heart block; twice-daily dosing.
• Carbonic anhydrase inhibitors (dorzolamide, brinzolamide topically; acetazolamide orally) — reduce aqueous production through ciliary body carbonic anhydrase inhibition; acetazolamide is used acutely in angle closure crisis.
• Alpha-2 agonists (brimonidine) — reduce aqueous production and increase uveoscleral outflow; useful as second-line or adjunct; systemic side effects include dry mouth, fatigue.
• Rho kinase inhibitors (netarsudil) — newest class; increases trabecular outflow directly; frequently causes conjunctival hyperaemia; useful in patients who cannot tolerate other classes.

Selective Laser Trabeculoplasty (SLT) applies 532 nm nanosecond pulses to pigmented trabecular meshwork cells, inducing a biological response that improves outflow facility. IOP reduction is typically 25–30% from baseline. SLT is repeatable (unlike earlier argon laser trabeculoplasty), non-thermal, and can serve as primary therapy or adjunct to drops. The LASER in Glaucoma and Ocular Hypertension (LiGHT) trial established SLT as equally effective as first-line eye drops with superior adherence outcomes.

When drops and laser fail to achieve target IOP, or when disease is advanced at presentation, surgery is indicated. Options range from minimally invasive to major:

• MIGS (Minimally Invasive Glaucoma Surgery) — a diverse group of procedures performed through a corneal incision, often combined with cataract surgery. Includes trabecular bypass stents (iStent), Kahook dual blade goniotomy, OMNI, and gonioscopy-assisted transluminal trabeculotomy (GATT). MIGS procedures offer modest IOP reduction (<5 mmHg typical) with excellent safety profiles; suitable for mild-moderate disease.
• Trabeculectomy — the gold standard surgical intervention for moderate-severe glaucoma. Creates a guarded fistula through the sclera, allowing aqueous to collect in a subconjunctival bleb. Reduces IOP by 40–50% in successful cases. Risk of hypotony, bleb-related infection (blebitis/endophthalmitis), and long-term failure with scarring.
• Tube shunt surgery (Ahmed, Baerveldt, Molteno implants) — for refractory or neovascular glaucoma where trabeculectomy has failed or is unlikely to succeed. A silicone tube shunts aqueous to an equatorial plate; more predictable than trabeculectomy in complex cases.

For acute angle-closure: emergency lowering of IOP with intravenous acetazolamide and topical agents, followed by laser peripheral iridotomy (LPI) — a small laser opening in the peripheral iris that equalises pressure between anterior and posterior chambers, reopening the drainage angle.

Most patients with glaucoma — or at risk of it — leave their eye examination without asking anything beyond "is my pressure okay?" These questions are worth asking. The doctors who welcome them are the doctors who have thought carefully about each patient's individual risk profile.